Appoints Garret Hampton and Alan Sachs to the Board
Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director
Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company’s next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company’s Board of Directors, effective immediately.
Dr. Hampton most recently served as President, Clinical Next Generation Sequencing and Oncology at Thermo Fisher Scientific. Dr. Sachs is the former Chief Medical Officer and Chief Scientific Officer of Thermo Fisher Scientific.
The Company also announced that Bill Donnelly, previously the non-Executive Chair of the Board, has been appointed Executive Chair, and Jeffrey Elliott, a current member of the Board, has been appointed to the newly created role of Lead Independent Director.
As Executive Chair, Mr. Donnelly will work closely with the Company’s leadership team and provide support in select strategic and operational areas. This structure enables Chief Executive Officer Masoud Toloue to continue advancing the Company’s key strategic initiatives, including expanding its blood- and tissue-based biomarker menu, launching LucentAD Complete™ for Alzheimer’s diagnosis, and accelerating growth synergies from the Akoya acquisition.
Additionally, Paul Meister and David Walt, Ph.D. are stepping down from the Board after many years of service, effective immediately.
With these changes, the Quanterix Board now comprises nine members, seven of whom are independent.
“On behalf of the Company, I am pleased to welcome Garret and Alan to the Board.” said Bill Donnelly, Executive Chair of the Board. “Their deep expertise in diagnostics, life sciences and product innovation will bring valuable perspectives to the Board. As we move beyond the integration stage and shift our focus toward growth, their combination of scientific insight, market knowledge, and experience in identifying and executing on growth opportunities will be invaluable.”
Mr. Donnelly added, “I would also like to thank Paul and David for their years of service and dedication to Quanterix. As our founding scientist and a pioneer in precision medicine, David has helped revolutionize the way pathologists detect and treat disease, while Paul, as a leading life sciences investor, has provided countless insights and contributions to our strategy. Both Paul and David have been instrumental in the Company’s growth, and we are deeply appreciative of the steady oversight and guidance they provided during their tenures. We wish them all the best.”
“I am excited to work with Garret and Alan who bring exceptional technical knowledge and business leadership to our Board,” said Masoud Toloue, CEO of Quanterix. “Bill’s expanded role will further strengthen our operational alignment and help accelerate the achievement of our growth initiatives. Together, these changes position the Company for continued leadership in the tools and diagnostics sector, advancing our mission to improve health outcomes for patients worldwide.”
“I look forward to working closely with Masoud and the rest of the leadership team at Quanterix to advance our strategic priorities,” added Mr. Donnelly. “With the acquisition of Akoya Biosciences now complete and the integration efforts advancing well, Quanterix is entering a new era. The Board and I are confident in the Company’s ability to deliver meaningful value in the coming years for our shareholders and for patients, partners, and other stakeholders.”